CL2022001492A1 - Nuevos inhibidores de braf como rompedores de la paradoja - Google Patents

Nuevos inhibidores de braf como rompedores de la paradoja

Info

Publication number
CL2022001492A1
CL2022001492A1 CL2022001492A CL2022001492A CL2022001492A1 CL 2022001492 A1 CL2022001492 A1 CL 2022001492A1 CL 2022001492 A CL2022001492 A CL 2022001492A CL 2022001492 A CL2022001492 A CL 2022001492A CL 2022001492 A1 CL2022001492 A1 CL 2022001492A1
Authority
CL
Chile
Prior art keywords
paradox
breakers
braf inhibitors
new
new braf
Prior art date
Application number
CL2022001492A
Other languages
English (en)
Inventor
Dolente Cosimo
Stephen HEWINGS David
Hunziker Daniel
Krummenacher Daniela
Francesco Tommaso Pettazzoni Piergiorgio
Wichmann Juergen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2022001492A1 publication Critical patent/CL2022001492A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I), en donde R1-R3 y X son como se definen en la descripción y en las reivindicaciones. El compuesto de la Fórmula (I) se puede usar como un medicamento.
CL2022001492A 2019-12-10 2022-06-07 Nuevos inhibidores de braf como rompedores de la paradoja CL2022001492A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19214867 2019-12-10

Publications (1)

Publication Number Publication Date
CL2022001492A1 true CL2022001492A1 (es) 2023-02-24

Family

ID=68848068

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001492A CL2022001492A1 (es) 2019-12-10 2022-06-07 Nuevos inhibidores de braf como rompedores de la paradoja

Country Status (17)

Country Link
US (1) US20220298145A1 (es)
EP (1) EP4073044A1 (es)
JP (1) JP2023505300A (es)
KR (1) KR20220112777A (es)
CN (1) CN114746405B (es)
AR (1) AR120697A1 (es)
AU (1) AU2020403082A1 (es)
BR (1) BR112022010633A2 (es)
CA (1) CA3158541A1 (es)
CL (1) CL2022001492A1 (es)
CO (1) CO2022007621A2 (es)
CR (1) CR20220252A (es)
IL (1) IL292349A (es)
MX (1) MX2022006711A (es)
PE (1) PE20221027A1 (es)
WO (1) WO2021116050A1 (es)
ZA (1) ZA202204092B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006783A (es) 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos derivados de metilquinazolinona.
WO2024054591A1 (en) * 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN118126051A (zh) * 2022-12-02 2024-06-04 C4医药公司 突变体braf降解剂的多晶型物及其制备方法
WO2024126634A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Process for the preparation of a quinazolinone derivative
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032873T2 (en) * 2008-03-17 2017-11-28 Ambit Biosciences Corp 1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP6186440B2 (ja) * 2012-09-19 2017-08-23 ノバルティス アーゲー キナーゼ阻害剤としてのジヒドロピロリジノピリミジン
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CN116096710A (zh) * 2020-06-09 2023-05-09 阿雷生物药品公司 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物

Also Published As

Publication number Publication date
US20220298145A1 (en) 2022-09-22
CR20220252A (es) 2022-07-11
KR20220112777A (ko) 2022-08-11
CA3158541A1 (en) 2021-06-17
CN114746405A (zh) 2022-07-12
CN114746405B (zh) 2024-03-26
JP2023505300A (ja) 2023-02-08
AR120697A1 (es) 2022-03-09
PE20221027A1 (es) 2022-06-16
EP4073044A1 (en) 2022-10-19
ZA202204092B (en) 2022-12-21
AU2020403082A1 (en) 2022-05-12
WO2021116050A1 (en) 2021-06-17
IL292349A (en) 2022-06-01
BR112022010633A2 (pt) 2022-08-16
TW202136218A (zh) 2021-10-01
CO2022007621A2 (es) 2022-08-30
MX2022006711A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
CL2022001492A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2020003361S1 (es) Cargador.
CL2020003360S1 (es) Cargador.
CL2020002696A1 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CO2021007056A2 (es) Nuevos compuestos heterocíclicos
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
CL2021000362A1 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
BR112015022804A2 (pt) novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
CO2022000481A2 (es) Inhibidores de enzimas
CR20160459A (es) Nuevos derivados de piridina
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
CL2023000594A1 (es) Compuestos heterocíclicos
CL2020003331A1 (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
PE20170440A1 (es) Derivados de isoindolina
CO2023014721A2 (es) Compuestos heterocíclicos
CO2022002336A2 (es) Compuestos heterocíclicos
CR20160448A (es) Nuevos derivados de piridina
CO2022000186A2 (es) Nuevos compuestos heterocíclicos